Precision’s Cash Runway Extended to YE 2024; No Major Clinical Updates; Precision BioSciences Q2 2022 Earnings Call Summary
On Monday, August 8, Precision BioSciences released their Q2 2022 earnings results (press release) highlighting PBCAR0191’s (allogeneic CD19 CAR-T) data readout in June 2022. Of note, no major updates were reported for PBCAR19B (allogeneic stealth CD19 CAR-T) or PBCAR269A (allogeneic BCMA CAR-T). Below, Celltelligence provides insights on PBCAR0191’s potential approval pathway, while discussing potential clinical delays for Precision’s MM programs.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.